Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: an update from the Australian Rheumatology Association Database (ARAD) prospective cohort study

被引：0
|
作者：
Margaret P. Staples
Lyn March
Catherine Hill
Marissa Lassere
Rachelle Buchbinder
机构：
[1] Cabrini Institute,Monash Department of Clinical Epidemiology
[2] Monash University,Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine
[3] Royal North Shore Hospital,Florance and Cope Professorial Department of Rheumatology
[4] Institute of Bone and Joint Research,Discipline of Medicine
[5] University of Sydney,undefined
[6] The Queen Elizabeth and Royal Adelaide Hospitals,undefined
[7] University of Adelaide,undefined
[8] St George Hospital,undefined
[9] University of New South Wales,undefined
来源：
BMC Rheumatology | / 3卷
关键词：
Rheumatoid arthritis; Malignancy; Tumour necrosis factor; Biologic therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 44 条
  • [1] Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: an update from the Australian Rheumatology Association Database (ARAD) prospective cohort study
    Staples, Margaret P.
    March, Lyn
    Hill, Catherine
    Lassere, Marissa
    Buchbinder, Rachelle
    BMC RHEUMATOLOGY, 2019, 3 (01)
  • [2] Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort study
    Rachelle Buchbinder
    Sharon Van Doornum
    Margaret Staples
    Marissa Lassere
    Lyn March
    BMC Musculoskeletal Disorders, 16
  • [3] Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort study
    Buchbinder, Rachelle
    Van Doornum, Sharon
    Staples, Margaret
    Lassere, Marissa
    March, Lyn
    BMC MUSCULOSKELETAL DISORDERS, 2015, 16
  • [4] Health-related quality of life and continuation rate on first-line anti-tumour necrosis factor therapy among rheumatoid arthritis patients from the Australian Rheumatology Association Database
    Staples, Margaret P.
    March, Lyn
    Lassere, Marissa
    Reid, Chris
    Buchbinder, Rachelle
    RHEUMATOLOGY, 2011, 50 (01) : 166 - 175
  • [5] Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
    Mercer, Louise K.
    Lunt, Mark
    Low, Audrey L. S.
    Dixon, William G.
    Watson, Kath D.
    Symmons, Deborah P. M.
    Hyrich, Kimme L.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (06) : 1087 - 1093
  • [6] Predictors for the 5-year risk of serious infections in patients with rheumatoid arthritis treated with anti-tumour necrosis factor therapy: a cohort study in the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry
    van Dartel, Sanne A. A.
    Fransen, Jaap
    Kievit, Wietske
    Dutmer, Ellen A. J.
    Brus, Herman L. M.
    Houtman, Nella M.
    van de Laar, Mart A. F.
    van Riel, Piet L. C. M.
    RHEUMATOLOGY, 2013, 52 (06) : 1052 - 1057
  • [7] Experiences and needs for work participation in employees with rheumatoid arthritis treated with anti-tumour necrosis factor therapy
    Van der Meer, Marrit
    Hoving, Jan L.
    Vermeulen, Marjolein I. M.
    Herenius, Marieke M. J.
    Tak, Paul P.
    Sluiter, Judith K.
    Frings-dresen, Monique H. W.
    DISABILITY AND REHABILITATION, 2011, 33 (25-26) : 2587 - 2595
  • [8] Immunogenicity of anti-tumour necrosis factor therapy in Korean patients with rheumatoid arthritis and ankylosing spondylitis
    Jung, Seung Min
    Kim, Hyun-Sook
    Kim, Hae-Rim
    Kim, Na Young
    Lee, Jung-Hwa
    Kim, Juryun
    Kwok, Seung-Ki
    Park, Kyung-Su
    Park, Sung-Hwan
    Kim, Ho-Youn
    Ju, Ji Hyeon
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2014, 21 (01) : 20 - 25
  • [9] Anti-tumour necrosis factor alpha therapy normalises fibrinolysis impairment in patients with active rheumatoid arthritis
    Ingegnoli, F.
    Fantini, F.
    Griffini, S.
    Soldi, A.
    Meroni, P. L.
    Cugno, M.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (02) : 254 - 257
  • [10] The impact of escalating conventional therapy in rheumatoid arthritis patients referred for anti-tumour necrosis factor-α therapy
    Bingham, SJ
    Buch, MH
    Tennant, A
    Emery, P
    RHEUMATOLOGY, 2004, 43 (03) : 364 - 368
12345